Tamoxifen maculopathy – A case with early optical coherence tomography changes

Abstract

<br>Tamoxifen is an antiestrogen agent used as adjuvant therapy in breast carcinoma. Crystalline maculopathy due to tamoxifen toxicity, though rare, causes irreversible changes in the retina. High-resolution imaging like spectral-domain optical coherence tomography (SD-OCT) can detect early degenerating changes like crystalline deposits and cavitation in the retina. Early detection helps in the prevention of visual loss by prompt consideration in discontinuing or replacing the drug. Periodic screening with SD-OCT is essential as structural changes in the retina are noted even in asymptomatic patients receiving low-dose tamoxifen.<br>